Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29109909 | 1.00 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL29841009 | 0.99 | TLR7 (0.58) | TLR7TLR8 | |
| SCHEMBL29840923 | 0.92 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL29840801 | 0.90 | TLR7 (0.68) | TLR7TLR8 | |
| SCHEMBL29840716 | 0.87 | TLR7 (0.64) | TLR7TLR8 | |
| SCHEMBL29840938 | 0.86 | TLR7 (0.63) | TLR7TLR8 | |
| SCHEMBL29841036 | 0.86 | TLR7 (0.63) | TLR7TLR8 | |
| SCHEMBL29840930 | 0.85 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL29841033 | 0.85 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL29840901 | 0.84 | TLR7 (0.63) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4288438-B1 | DERIVATIVES OF IMIDAZO[4,5-D]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2026-02-18 | — | — | EP | claimed |
| EP-4288438-A1 | DERIVATIVES OF IMIDAZO[4,5-D]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Sanofi (FR) | 2023-12-13 | — | — | EP | claimed |
| CN-117098761-A | Imidazo [4,5-d ] pyridazine derivatives, preparation thereof and therapeutic use thereof | 赛诺菲 | 2023-11-21 | — | — | CN | claimed |
| WO-2022167438-A1 | DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2022-08-11 | — | — | WO | claimed |
| US-12583861-B2 | Derivatives of imidazo[4,5-d]pyridazine, their preparation and their therapeutic application | SANOFI (FR) | 2026-03-24 | — | — | US | disclosed |
| WO-2025031923-A1 | IMIDAZO[4,5-D]PYRIDAZINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS | SANOFI (FR) | 2025-02-13 | — | — | WO | disclosed |
| US-20240158401-A1 | DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2024-05-16 | — | — | US | disclosed |
| EP-4288438-A1 | DERIVATIVES OF IMIDAZO[4,5-D]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Sanofi (FR) | 2023-12-13 | — | — | EP | disclosed |
| CN-117098761-A | Imidazo [4,5-d ] pyridazine derivatives, preparation thereof and therapeutic use thereof | 赛诺菲 | 2023-11-21 | — | — | CN | disclosed |
| WO-2022167438-A1 | DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583861-B2 | Derivatives of imidazo[4,5-d]pyridazine, their preparation and their therapeutic application | TLR7, TLR8, TLR6 | TLR7 1/4885TLR8 2/4885 |
| US-20240158401-A1 | DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | TLR7, TLR8, TLR6 | TLR7 1/4885TLR8 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.